1 domain / 2 areas / 2 specializations
RA Capital Management
Also known as: RA Capital Management, L.P., RA Capital
Data updated
RA Capital Management is a large, multi-stage healthcare and life-sciences investment manager that funds and builds companies across a wide development spectrum. Its public materials stress evidence-based investing, company formation, and deep scientific diligence.
For psychedelic medicine, RA Capital is relevant because it publicly lists Delix Therapeutics in its venture portfolio and Delix financing materials identify RA as a lead investor in the company's Series A. This is a strong psychedelic-adjacent record, while RA remains best framed as a broad life-sciences investor.
Investor Context
Institutional InvestorsInvestment Context
This stakeholder is listed as an Institutional Investor within Institutional Investors. Its public geography context is global. Public stage signals include Seed, Series A/B, Growth / Late Stage, Public Markets, and Multi-Stage. Public focus areas include Drug Development, Clinical Infrastructure, and Manufacturing & Supply Chain.
Public Portfolio Examples
- Delix TherapeuticsSeries A - $70 million - Sep 27, 2021
Delix Therapeutics is the anchor psychedelic-adjacent record for RA Capital. The profile should emphasize RA's broad life-science platform and avoid presenting the firm as psychedelic-dedicated.
Investor Type
Institutional Investor
Geographic Scope
Global
Psychedelic Focus
Psychedelic-Adjacent Focus
Engagement
Active
Investment Stage Focus
Investment Focus Areas
Portfolio Stakeholders
Recorded Investments
Sep 27, 2021
Series A - $70 million
Confirms RA as a lead investor in a non-hallucinogenic psychedelics-adjacent neuropsychiatry company.
Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain DisordersQuick Facts
- Founded
- 2004
- HQ
- Boston, Massachusetts, United States
- Website
- Visit